153Sm-EDTMP与云克联合治疗转移性骨肿瘤疼痛的临床价值

为探讨^153Sm-EDTMP（^153钐－乙二胺四亚甲基膦酸）与云克（^99Tc-MDP，即^99锝－亚甲基二膦酸盐）联合治疗转移性骨肿瘤疼痛的临床价值。对210例癌骨转移患者分别为^153Sm-EDTMP单独治疗或与云克联合治疗，观察其疗效。结果显示，^153Sm-EDTMP单独治疗组，止痛有效率为83．7％，转移灶消失或缩小的总有效率为21．6％；^153Sm-EDTMP与云克静脉滴注联合治疗组，止痛有效率为94．7％，转移灶消失或缩小的总有效率为35．1％。后者明显高于单独治疗组。表明^153Sm-EDTMP联合云克静脉滴注对恶性肿瘤多发性骨转移所致疼痛有明显疗效，且安全无副作用。联合治疗组疗效优于单独治疗组。

Clinical value of combined 153Sm-EDTMP and Yunke therapy for relief of metastatic bony pain

To evaluate the clinical value of combined 153 Sm-EDTMP and Yunke therapy in metastatic bony pain. 210 patients with metastatic bony pain were treated using 153 Sm-EDTMP or combined with Yunke. The effect of treatment were observed. The total pain relief rate in single 153 Sm-EDTMP group was 83.7%, whereas in combined 153 Sm-EDTMP with Yunke group was 94.7%. The latter was markedly higher than the former. The clinical value of combined 153 Sm-EDTMP and Yunke therapy group in relief of metastatic bony pain is obvious. And it was safe and no significant adverse reaction was observed. The pain relief effect of combined 153 Sm-EDTMP and Yunke therapy is better than the single 153 Sm-EDTMP therapy.